| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ... The lancet Diabetes & endocrinology 7 (11), 845-854, 2019 | 818 | 2019 |
| Sex differences in heart failure CSP Lam, C Arnott, AL Beale, C Chandramouli, D Hilfiker-Kleiner, ... European heart journal 40 (47), 3859-3868c, 2019 | 611 | 2019 |
| Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study K Vaidya, C Arnott, GJ Martínez, B Ng, S McCormack, DR Sullivan, ... JACC: Cardiovascular Imaging 11 (2 Part 2), 305-316, 2018 | 267 | 2018 |
| Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ... Journal of the American Heart Association 9 (3), e014908, 2020 | 236 | 2020 |
| Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data GA Figtree, ST Vernon, N Hadziosmanovic, J Sundström, J Alfredsson, ... The Lancet 397 (10279), 1085-1094, 2021 | 210 | 2021 |
| Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials BL Neuen, M Oshima, R Agarwal, C Arnott, DZ Cherney, R Edwards, ... Circulation 145 (19), 1460-1470, 2022 | 173 | 2022 |
| Colchicine in cardiovascular disease: in-depth review SG Deftereos, FJ Beerkens, B Shah, G Giannopoulos, DA Vrachatis, ... Circulation 145 (1), 61-78, 2022 | 145 | 2022 |
| Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial BL Neuen, M Oshima, V Perkovic, R Agarwal, C Arnott, G Bakris, ... European heart journal 42 (48), 4891-4901, 2021 | 108 | 2021 |
| Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes JW Li, B Neal, V Perkovic, D de Zeeuw, BL Neuen, C Arnott, R Simpson, ... Kidney international 98 (3), 769-777, 2020 | 96 | 2020 |
| Sex differences in primary and secondary prevention of cardiovascular disease in China S Xia, X Du, L Guo, J Du, C Arnott, CSP Lam, MD Huffman, H Arima, ... Circulation 141 (7), 530-539, 2020 | 95 | 2020 |
| Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial N Ye, MJ Jardine, M Oshima, C Hockham, HJL Heerspink, R Agarwal, ... Circulation 143 (18), 1735-1749, 2021 | 78 | 2021 |
| Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors L Geraghty, GA Figtree, AE Schutte, S Patel, M Woodward, C Arnott Heart, Lung and Circulation 30 (1), 9-17, 2021 | 75 | 2021 |
| Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial T Sen, J Li, BL Neuen, B Neal, C Arnott, CR Parikh, SG Coca, V Perkovic, ... Diabetologia 64 (10), 2147-2158, 2021 | 59 | 2021 |
| Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes BL Neuen, C Arnott, V Perkovic, G Figtree, D de Zeeuw, G Fulcher, M Jun, ... Diabetes, Obesity and Metabolism 23 (2), 382-390, 2021 | 58 | 2021 |
| Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial J Yu, SR Thout, Q Li, M Tian, M Marklund, C Arnott, MD Huffman, ... The American journal of clinical nutrition 114 (1), 185-193, 2021 | 54 | 2021 |
| Maternal cardiovascular risk after hypertensive disorder of pregnancy C Arnott, M Nelson, MA Ramirez, J Hyett, M Gale, A Henry, DS Celermajer, ... Heart 106 (24), 1927-1933, 2020 | 54 | 2020 |
| A systematic review of vascular structure and function in pre-eclampsia: non-invasive assessment and mechanistic links S Kirollos, M Skilton, S Patel, C Arnott Frontiers in cardiovascular medicine 6, 166, 2019 | 54 | 2019 |
| Prognostic value of secreted frizzled-related protein 5 in heart failure patients with and without type 2 diabetes mellitus J Wu, H Zheng, X Liu, P Chen, Y Zhang, J Luo, J Kuang, J Li, Y Yang, ... Circulation: Heart Failure 13 (9), e007054, 2020 | 50 | 2020 |
| Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis Y Yang, W Li, H Zhu, XF Pan, Y Hu, C Arnott, W Mai, X Cai, Y Huang bmj 369, 2020 | 50 | 2020 |
| Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study B Tucker, R Kurup, J Barraclough, R Henriquez, S Cartland, C Arnott, ... Clinical therapeutics 41 (10), 2172-2181, 2019 | 47 | 2019 |
